Business
GSK - third tranche of share buyback programme
GSK plc announced the commencement of the third tranche of its share buyback program, which was initially announced on February 24, 2025. This third tranche, valued at up to £0.3 billion, will allow GSK to repurchase ordinary shares of 31¼ pence each. Purchases under this tranche are expected to begin on September 30, 2025, and conclude by December 19, 2025. The initial tranche of up to £0.7 billion commenced on February 24, 2025 and completed on June 3, 2025, while the second tranche of up to £0.45 billion commenced on June 4, 2025 and completed on September 18, 2025. The purpose of the overall program is to return excess capital to shareholders and reduce the company's share capital. Disclaimer*
About this update from Gsk Plc
[{"type":"text","content":"\n\nIssued: 30 September 2025, London UK\n \n \nGSK plc announces the third tranche of share buyback programme\n \n\nOn 24 February 2025, GSK plc (\"GSK\") announced the commencement of a £2 billion share buyback programme (the \"Programme\"), as announced in its 2024 full year results announcement published on 5 February 2025. The Programme is to be implemented over the period to the end of Q2 2026.\nThe first tranche of the Programme (of up to £0.7 billion) commenced on 24 February 2025 and completed on 3 June 2025, in accordance with its terms. The second tranche of the Programme (of up to £0.45 billion) commenced on 4 June 2025 and completed on 18 September 2025, in accordance with its terms.\nGSK announces that the third tranche of the Programme of up to £0.3 billion will commence today.\nGSK has entered into a non-discretionary agreement with BNP Paribas S.A. (\"BNPP\"), enabling GSK to buy back ordinary shares of 31¼ pence each in GSK (\"Ordinary Shares\") with an aggregate value of up to £0.3 billion (the \"Third Tranche\"). Purchases of Ordinary Shares under the Third Tranche are expected to commence on 30 September 2025 and to be completed by 19 December 2025.\nThe purpose of the Programme is to return excess capital to shareholders and reduce the share capital of the company, and it is expected that the implementation of the Programme will enhance earnings per share. Ordinary Shares purchased under the Third Tranche will be held as Treasury shares.\nBNPP will make trading decisions in relation to the Third Tranche independently of GSK with regard to the timing of purchases. Any purchase of Ordinary Shares by BNPP contemplated by this announcement will be carried out on the London Stock Exchange and/or Cboe Europe Limited through the BXE and CXE order books. Any purchases of Ordinary Shares by GSK from BNPP under the Third Tranche will be carried out on the London Stock Exchange.\nThe Third Tranche will be effected within certain pre-set parameters and in accordance with GSK's general authority to repurchase shares and will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014, the Commission Delegated Regulation (EU) 2016/1052 (both as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) as well as applicable laws and the regulations of the UK Fi...